|
90
|
387
|
5kr8A |
(4~{s},6~{s})-4-[2,4-bis(fluoranyl)phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine (compound 5) bound to bace1 |
|
90
|
387
|
5ie1A |
Crystal structure of bace1 in complex with 3-(2-amino-6-(o-tolyl)quinolin-3-yl)-n-(3,3-dimethylbutyl)propanamide |
|
100
|
389
|
5i3xA |
Crystal structure of bace1 in complex with aminoquinoline inhibitor 6 |
|
92
|
388
|
5i3wA |
Crystal structure of bace1 in complex with 2-aminooxazoline-3-azaxanthene inhibitor 2 |
|
94
|
387
|
5i3yA |
Crystal structure of bace1 in complex with aminoquinoline inhibitor 9 |
|
104
|
390
|
5hu0A |
Bace1 in complex with 4-(3-(furan-2-carboxamido)phenyl)-1-methyl-5-oxo-4-phenylimidazolidin-2-iminium |
|
107
|
391
|
5htzA |
Bace1 in complex with (s)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3-yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1-dioxide |
|
102
|
391
|
5hu1A |
Bace1 in complex with (r)-n-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropicolinamide |
|
102
|
390
|
5ezxA |
Crystal structure of bace-1 in complex with {(1r,2r)-2-[(r)-2-amino-4-(4-difluoromethoxy-phenyl)-4,5-dihydro-oxazol-4-yl]-cyclopropyl}-(5-chloro-pyridin-3-yl)-methanone |
|
105
|
390
|
6fgyA |
Crystal structure of human bace-1 in complex with amino-1,4-oxazine compound 4 |
|
103
|
388
|
6eqmA |
Crystal structure of human bace-1 in complex with cnp520 |
|
99
|
409
|
6ej2A |
Bace1 compound 28 |
|
95
|
387
|
6ej3A |
Bace1 compound 23 |
|
100
|
389
|
6dhcA |
X-ray structure of bace1 in complex with a bicyclic isoxazoline carboxamide as the p3 ligand |
|
95
|
388
|
6c2iA |
Structure of bace-1 (beta-secretase) in complex with : n-(3-((1r,5s,6r)-3-amino-5-methyl-2-oxa-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4-fluorophenyl)-5-methoxypyrazine-2-carboxamide |
|
106
|
393
|
6bfdA |
Bace crystal structure with hydroxy pyrrolidine inhibitor |
|
105
|
389
|
6bfxA |
Bace crystal structure with hydroxy pyrrolidine inhibitor |
|
105
|
393
|
6bfwA |
Bace crystal structure with hydroxy morpholine inhibitor |
|
106
|
393
|
6bfeA |
Bace crystal structure with hydroxy pyrrolidine inhibitor |
|
98
|
392
|
5ygyA |
Crystal structure of bace1 in complex with (s)-n-(3-(2-amino-6-(fluoromethyl)-4 -methyl-4h-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide |
|
98
|
389
|
5ygxA |
Structure of bace1 in complex with n-(3-((4r,5r,6s)-2-amino-6-(1,1-difluoroethyl)-5-fluoro-4-methyl-5,6-dihydro-4h-1,3-oxazin-4-yl)-4-fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide |
|
99
|
387
|
5uyuA |
Crystal structure of bace1 in complex with 2-aminooxazoline-3-azaxanthene compound 12 |
|
99
|
386
|
4exgA |
Design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors |
|
99
|
386
|
4ewoA |
Design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors |
|
97
|
387
|
4dpiA |
Bace-1 in complex with hea-macrocyclic inhibitor, mv078512 |
|
94
|
388
|
4dvfA |
Crystal structure of bace1 with its inhibitor |
|
99
|
387
|
4dpfA |
Bace-1 in complex with a hea-macrocyclic type inhibitor |
|
91
|
387
|
4dusA |
Structure of bace-1 (beta-secretase) in complex with n-((2s,3r)-1-(4-fluorophenyl)-3-hydroxy-4-((6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridin]-4'-yl)amino)butan-2-yl)acetamide |
|
94
|
391
|
4dv9A |
Crystal structure of bace1 with its inhibitor |
|
104
|
390
|
4djyA |
Structure of bace bound to (r)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5-(prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one |
|
95
|
388
|
4d83A |
Crystal structure of human beta secretase in complex with nvp-bur436, derived from a co-crystallization experiment |
|
90
|
387
|
4dh6A |
Structure of bace-1 (beta-secretase) in complex with (2r)-n-((2s,3r)-1-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-4-((s)-6'-neopentyl-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-b]pyridine]-4'-ylamino)butan-2-yl)-2-methoxypropanamide |
|
104
|
390
|
4djxA |
Structure of bace bound to 5-(3-(5-chloropyridin-3-yl)phenyl)-5-cyclopropyl-2-imino-3-methylimidazolidin-4-one |
|
106
|
390
|
4djvA |
Structure of bace bound to 2-imino-5-(3'-methoxy-[1,1'-biphenyl]-3-yl)-3-methyl-5-phenylimidazolidin-4-one |
|
101
|
389
|
4d85A |
Crystal structure of human beta secretase in complex with nvp-bvi151 |
|
105
|
390
|
4djuA |
Structure of bace bound to 2-imino-3-methyl-5,5-diphenylimidazolidin-4-one |
|
100
|
391
|
4di2A |
Crystal structure of bace1 in complex with hydroxyethylamine inhibitor 37 |
|
99
|
388
|
4d8cA |
Crystal structure of human beta secretase in complex with nvp-bxd552, derived from a co-crystallization experiment |
|
104
|
390
|
4djwA |
Structure of bace bound to 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3-yl)phenyl)imidazolidin-4-one |
|
101
|
388
|
4d89A |
Crystal structure of human beta secretase in complex with nvp-bxd552, derived from a soaking experiment |
|
99
|
388
|
4d88A |
Crystal structure of human beta secretase in complex with nvp-bxq490 |
|
104
|
388
|
4b1dA |
New aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain |
|
102
|
388
|
4b77A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
104
|
388
|
4azyA |
Design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound 10) |
|
102
|
389
|
4b05A |
Preclinical characterization of azd3839, a novel clinical candidate bace1 inhibitor for the treatment of alzheimer disease |
|
102
|
384
|
4b78A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
100
|
385
|
4b70A |
Aminoimidazoles as bace-1 inhibitors: from de novo design to ab- lowering in brain |
|
102
|
388
|
4b00A |
Design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound (r)-41) |
|
102
|
390
|
4bfdA |
Crystal structure of bace-1 in complex with chemical ligand |
|
101
|
388
|
4b1eA |
New aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain |
